# Bayer HealthCare

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/bayer-healthcare/

## Facts

| Field | Value |
| --- | --- |
| Country | DE |
| Description | German multinational pharmaceutical, chemical, and agricultural biotechnology company |
| OpenAlex ID | https://openalex.org/F4320320303 |
| ROR ID | https://ror.org/04hmn8g73 |
| Works | 5,705 |

## Funder papers

- [Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial](https://scholariq.org/papers/safety-and-tolerability-of-the-novel-non-steroidal-mineralocorticoid-receptor/)
- [Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial](https://scholariq.org/papers/long-term-kidney-outcomes-of-semaglutide-in-obesity-and-cardiovascular-disease/)
- [KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary](https://scholariq.org/papers/kdigo-2025-clinical-practice-guideline-for-the-evaluation-management-and/)
- [A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease](https://scholariq.org/papers/a-comparative-post-hoc-analysis-of-finerenone-and-spironolactone-in-resistant/)
- [A Review and Comparative Case Study Analysis of Real-World Evidence in European Regulatory and Health Technology Assessment Decision Making for Oncology Medicines](https://scholariq.org/papers/a-review-and-comparative-case-study-analysis-of-real-world-evidence-in-european/)
- [Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial](https://scholariq.org/papers/simultaneous-initiation-of-finerenone-and-empagliflozin-across-the-spectrum-of/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.